Published by Josh White on 11th December 2017
(ShareCast News) - Virtual pharmaceutical company Evgen announced on Monday that it was progressing in Phase II clinical trials of SFX-01 for both subarachnoid haemorrhage and ER+ breast cancer, with readouts expected at or around the end of 2018.
URL: http://www.digitallook.com/dl/news/story/26809657/...